Incorporating New Therapeutic Tools for Migraine Prevention: An Expert-Guided Discussion

Incorporating New Therapeutic Tools for Migraine Prevention: An Expert-Guided Discussion - Pre-Activity Survey

CME/CE Information

Activity Progress
Pre-Activity Survey
Page 1
Post-Activity Survey
CME Evaluation/Print Certificate

How often do you engage patients in shared decision-making to develop a tailored approach to migraine preventive therapy based on patient preferences and the best clinical evidence?* Always
Very often
Sometimes
Rarely
Never
According to the American Headache Society (AHS) position statement, which of the following patients should be offered preventive treatment for migraine?* A 37-year-old man with 2 headache days per month and some disability
A 43-year-old woman with 3 headache days per month and no disability
A 32-year-old woman with 4 headache days per month and some disability
Not sure
According to the phase 4 head-to-head study that compared erenumab to topiramate for migraine prophylaxis, what percentage of patients discontinued erenumab due to adverse events?* 10.6%
27.4%
38.9%
Not sure
Ms Carter is a 29-year-old female with a 4-year history of episodic migraine. Her migraines occur approximately 8 times per month, causing her to miss time from work on occasion. In the past, she has tried over-the-counter analgesics, propranolol and amitriptyline, and has experienced some relief with eletriptan. During a discussion of alternative preventive strategies, Ms Carter states she does not like taking injections and would like to start a family in the near future. Which of the following migraine preventive therapies would be best?* Erenumab
Galcanezumab
Rimegepant
Not sure
Mr Park is a 33-year-old man who presents with complaints of 17 days of headache per month, with 6 of those being severe. He has trialed topiramate, amitriptyline, and propranolol which he did not tolerate due to adverse events and did not experience adequate relief with onabotulinumtoxinA. Which of the following migraine preventive therapies would be best?* Erenumab
Rimegepant
Sumatriptan
Not sure

Save and Proceed

Incorporating New Therapeutic Tools for Migraine Prevention: An Expert-Guided Discussion

Jessica Ailani, MD, FAHS, FAAN

Susan L. Hutchinson, MD

Release Date: March 18, 2022
Expiration Date: March 18, 2023

Continue to Activity

Statement of Need/Program Overview

Looking for guidance on who may benefit from calcitonin gene-related peptide (CGRP)-targeted therapies for migraine prevention? Unsure which migraine preventive therapy may be best for your patient? In this CliniClip activity, Drs Jessica Ailani and Susan Hutchinson use real-world patient scenarios to share their expert insights on who may benefit from a CGRP-targeted therapy and highlight when a small molecule or a monoclonal antibody may be appropriate for migraine prevention.

Target Audience
The target audience will be neurologists, primary care physicians, and advanced practice providers in neurology and primary care.

Educational Objectives
Upon completion of this educational activity, learners should be better able to:

IDENTIFY patients who are candidates for newer pharmacologic therapy for prevention of migraines
ASSESS relevant clinical efficacy and safety data for new and recently approved prevention strategies for migraine
DESIGN an individualized migraine prevention plan according to the best available evidence and patient preferences

Faculty
Jessica Ailani, MD, FAHS, FAAN

Director, MedStar Georgetown Headache Center
Vice Co-Chair, Strategic Planning
Professor of Clinical Neurology
MedStar Georgetown University Hospital
Washington, DC

Susan L. Hutchinson, MD
Headache Specialist
Director and Founder, Orange County Migraine & Headache Center
Irvine, CA

Providership & Support

This educational activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning.

This activity is supported by educational funding provided by Amgen and Biohaven Pharmaceuticals.

Disclosures of Conflicts of Interest

The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States.

All relevant financial relationships listed below have been mitigated.

The ACCME defines an ineligible company as those who primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty

Jessica Ailani, MD, FAHS, FAAN (Chair)
Director, MedStar Georgetown Headache Center
Vice Co-Chair, Strategic Planning
Professor of Clinical Neurology
MedStar Georgetown University Hospital
Washington, DC

Disclosure
Advisor: AbbVie; Amgen; Axsome Therapeutics; BioDelivery Sciences International; Biohaven Pharmaceuticals; Eli Lilly and Company; Impel NeuroPharma, Inc; Lundbeck; Satsuma Pharmaceuticals, Inc; Teva; Theranica Bio-Electronics Ltd
Consultant: AbbVie; Amgen; BioDelivery Sciences International; Biohaven Pharmaceuticals; Eli Lilly and Company; GlaxoSmithKline; Impel NeuroPharma, Inc; Lundbeck; Satsuma Pharmaceuticals, Inc; Teva; Theranica Bio-Electronics Ltd
Clinical Trial Principal Investigator: AbbVie; Biohaven Pharmaceuticals; Eli Lilly and Company; Satsuma Pharmaceuticals, Inc

David M. Kaufman, MD (Co-Chair)

Professor, The Saul R. Korey Department of Neurology

Professor, Department of Psychiatry and Behavioral Sciences

Albert Einstein College of Medicine

Montefiore Medical Center

Bronx, NY

Disclosure

Dr. Kaufman has no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Susan L. Hutchinson, MD
Headache Specialist
Director and Founder, Orange County Migraine & Headache Center
Irvine, CA

Disclosure
Advisor: AbbVie; Amgen; Biohaven Pharmaceuticals; Currax Pharmaceuticals LLC; Eli Lilly and Company; Impel NeuroPharma, Inc; Lundbeck; Novartis (relationship has ended); Teva; Theranica Bio-Electronics Ltd; Upsher-Smith Laboratories, LLC
Consultant: AbbVie; Amgen; Biohaven Pharmaceuticals; Currax Pharmaceuticals LLC; Eli Lilly and Company; Impel NeuroPharma, Inc; Lundbeck; Novartis (relationship has ended); Teva; Theranica Bio-Electronics Ltd; Upsher-Smith Laboratories, LLC
Speaker: AbbVie; Amgen; Biohaven Pharmaceuticals; Eli Lilly and Company; Impel NeuroPharma, Inc; Lundbeck; Novartis (relationship has ended); Teva; Theranica Bio-Electronics Ltd; Upsher-Smith Laboratories, LLC

Educational Planning Committee
Spire Learning Disclosures
Mairead Early (Program Manager), Allison Goldberg, MPA (Senior Director, Grants and Education), and Chris Washburn, PhD (Clinical Director) have no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Reviewers

David M. Kaufman, MD (Peer Reviewer)
Professor, The Saul R. Korey Department of Neurology
Professor, Department of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Disclosure
Dr. Kaufman has no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Victor B. Hatcher, PhD (CME Reviewer)
Associate Dean, Continuing Professional Development
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York

Disclosure
Dr. Hatcher has no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Disclosure of Unlabeled or Investigational Use
This educational activity does not contain discussion of unlabeled and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Privacy Policy
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME.

Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.

Additional information regarding Albert Einstein College of Medicine-Montefiore Medical Center’s Privacy Policy can be viewed at https://www.mecme.org/PrivacyStatement.aspx

Spire Learning Privacy Policy - https://www.spirelearning.com/privacy-policy/

Copyright Information
Copyright © 2022 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Spire Learning. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Albert Einstein College of Medicine-Montefiore Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

There are no fees to participate in this educational activity. To receive credit:
• Read the learning objectives, disclosure statements, and other introductory CME information
• Complete the preassessment prior to the start of the activity
• Participate in the online enduring activity
• Complete the postassessment with a passing grade of 80% or higher, and evaluation at the conclusion of the activity

If you are seeking credit, you must complete the postassessment and evaluation at the conclusion of the activity.

For information about the accreditation of this activity, please contact Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) at cme@montefiore.org or 718-920-6674.

For technical assistance, please contact Spire Learning at mearly@spirelearning.com.

Incorporating New Therapeutic Tools for Migraine Prevention: An Expert-Guided Discussion - Pre-Activity Survey

Incorporating New Therapeutic Tools for Migraine Prevention: An Expert-Guided Discussion

References for Incorporating New Therapeutic Tools for Migraine Prevention: An Expert-Guided Discussion